GLP-1 vs Semaglutide vs Tirzepatide: What's the Difference?

If you have spent any time reading about weight-loss medications recently, you have probably encountered three terms that seem to be used almost interchangeably: GLP-1, semaglutide, and tirzepatide.

A friend might say, "I started GLP-1." A news headline might read, "Semaglutide vs tirzepatide: which is better?" And somewhere in the middle, you are left wondering whether these are three names for the same thing or three completely different medicines.

The confusion is understandable. These terms are related but they sit at different levels of a hierarchy. Getting that hierarchy clear is the first step to making informed decisions about your health. So let us sort it out once and for all.

Let us start at the top. GLP-1 is not a medicine. It is a hormone — glucagon-like peptide-1 — that your body naturally produces in your gut after you eat. This hormone helps regulate blood sugar, slows gastric emptying, and sends fullness signals to your brain.

When doctors and headlines refer to "GLP-1 medications" or "GLP-1 receptor agonists," they are talking about an entire class of drugs — a family of medicines that all work by mimicking this natural hormone. Think of it like saying "painkillers" — that is a class that includes paracetamol, ibuprofen, aspirin, and dozens of others. Saying "I take a painkiller" does not tell you which specific medicine someone uses.

Similarly, saying "I am on a GLP-1" does not tell you the specific molecule. The GLP-1 receptor agonist class includes several medicines:

• Semaglutide (brands: Ozempic, Wegovy, Rybelsus)
• Liraglutide (brands: Victoza, Saxenda)
• Dulaglutide (brand: Trulicity)
• Exenatide (brands: Byetta, Bydureon)
• Tirzepatide (brand: Mounjaro) — with an important caveat we will get to shortly

Each of these molecules mimics GLP-1, but they differ in potency, duration of action, dosing frequency, clinical evidence, and approved uses. Lumping them all together as "GLP-1" hides these important differences.

Semaglutide is a specific molecule within the GLP-1 class. It was developed by Novo Nordisk and is currently available under several brand names:

• Ozempic — a once-weekly injection approved for type 2 diabetes
• Wegovy — a once-weekly injection at a higher dose, approved for chronic weight management
• Rybelsus — a daily oral tablet approved for type 2 diabetes

Semaglutide works by binding to GLP-1 receptors in your body — the same receptors your natural GLP-1 hormone uses. But unlike your natural hormone, which breaks down within minutes, semaglutide is engineered to last about a week in your system. This sustained action is what makes it so effective.

What the Evidence Shows

The clinical evidence behind semaglutide is extensive. The STEP trial programme, involving thousands of participants across multiple countries, demonstrated average weight loss of approximately 15% of body weight over 68 weeks in adults with obesity. In the SELECT trial, semaglutide also showed a 20% reduction in major adverse cardiovascular events — a finding that changed how the medical community views this medication.

These results made semaglutide a household name and, in many ways, the medicine that brought GLP-1 therapy into mainstream awareness.

Tirzepatide is where things get particularly interesting — and where the simple label of "GLP-1 medicine" starts to break down.

Developed by Eli Lilly, tirzepatide is sold under the brand name Mounjaro (for type 2 diabetes) and Zepbound (for weight management, approved in the United States). Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide is a dual agonist. It activates two types of receptors simultaneously:

• GLP-1 receptors — the same ones semaglutide targets, which regulate appetite, blood sugar, and gastric emptying
• GIP receptors — GIP stands for glucose-dependent insulinotropic polypeptide, another gut hormone involved in insulin secretion, fat metabolism, and energy regulation

Think of it this way: if semaglutide plays one instrument very well, tirzepatide plays two instruments at the same time. The combination of GLP-1 and GIP activation appears to produce complementary metabolic effects that neither pathway achieves alone.

What the Evidence Shows

The SURMOUNT trial programme tested tirzepatide specifically for weight management. The results were striking. In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of approximately 22.5% of their body weight over 72 weeks — with some participants losing even more.

These numbers represent the largest average weight loss achieved by any non-surgical treatment in clinical trial history. The SURPASS trials for diabetes also showed strong efficacy in blood sugar control, often outperforming semaglutide in head-to-head comparisons.

It is important to note, however, that tirzepatide is newer. Its long-term safety data, cardiovascular outcome data, and real-world experience are still accumulating compared to semaglutide, which has a longer track record.

Let us put the main differences side by side so you can see them clearly.

Mechanism of Action

• Semaglutide: Activates GLP-1 receptors only (single agonist)
• Tirzepatide: Activates both GLP-1 and GIP receptors (dual agonist)

Approved Brands and Uses

• Semaglutide: Ozempic (diabetes), Wegovy (weight management), Rybelsus (diabetes, oral form)
• Tirzepatide: Mounjaro (diabetes), Zepbound (weight management — US approval)

Dosing

• Semaglutide (Wegovy): Once weekly, titrated from 0.25 mg up to 2.4 mg
• Tirzepatide (Mounjaro): Once weekly, titrated from 2.5 mg up to 15 mg

Average Weight Loss in Trials

• Semaglutide 2.4 mg: Approximately 15% of body weight over 68 weeks (STEP 1)
• Tirzepatide 15 mg: Approximately 22.5% of body weight over 72 weeks (SURMOUNT-1)

Cardiovascular Outcome Data

• Semaglutide: SELECT trial showed 20% reduction in major cardiovascular events in adults with obesity and established heart disease
• Tirzepatide: Dedicated cardiovascular outcomes trial is ongoing; no completed CVOT data yet

Side Effect Profile

• Both medicines share similar gastrointestinal side effects — nausea, constipation, diarrhoea, and vomiting — especially during dose escalation. The overall tolerability profiles in clinical trials were broadly comparable, though direct comparisons should be interpreted carefully.

Availability in India

• Drug availability in India depends on approvals by the Central Drugs Standard Control Organisation (CDSCO). Not all formulations or indications approved internationally are necessarily available in India. Your clinician will know what is currently accessible and approved in your region.

It is tempting to look at the numbers above and conclude that tirzepatide is "better" because it produced more weight loss in trials. But this kind of comparison, while common in headlines, oversimplifies reality in important ways.

Different Trials, Different Populations

The STEP and SURMOUNT trials were conducted separately. The participant populations were not identical. The trial designs, durations, and supportive measures differed. Comparing averages from different studies is not the same as running a controlled head-to-head experiment with the same patients.

Averages Hide Individual Variation

When we say "average weight loss of 15%" or "22.5%," that is a mean across thousands of participants. Some people lost much more than the average. Some lost less. Your individual response depends on your genetics, metabolism, adherence, diet, activity level, starting weight, and many other factors that no trial average can predict.

More Is Not Always the Goal

For many patients, 10-15% body weight loss is enough to produce transformative health improvements — reduced blood pressure, improved blood sugar control, better sleep, less joint pain. The clinical target is not "maximum possible weight loss" but rather "enough weight loss to meaningfully improve your health and quality of life."

Safety and Track Record Matter

Semaglutide has several more years of post-marketing safety data and a completed cardiovascular outcomes trial. Tirzepatide is newer and its long-term profile is still being established. For some patients and clinicians, this longer track record may be a meaningful factor in their decision.

The honest answer to "which is better" is: it depends on you. Your medical history, your treatment goals, your tolerance for side effects, what is available in your country, and your clinician's assessment all shape the right choice.

Here is the part where we resist the temptation to give you a definitive ranking — because medicine does not work that way.

The choice between semaglutide and tirzepatide (or any other GLP-1 therapy) is a clinical decision that should be made between you and your doctor. It depends on:

• Your diagnosis: Are you managing type 2 diabetes, obesity, or both?
• Your medical history: Do you have any conditions that favour one medicine over another?
• What is approved and available: Regulatory approvals and drug availability vary by country. In India, CDSCO approvals determine what can legally be prescribed.
• Your prior treatment experience: Have you tried one of these medicines before? How did your body respond?
• Cost and access: Pricing, insurance coverage, and pharmacy availability differ between these medications.
• Your clinician's expertise: An experienced doctor who understands your full health picture is in the best position to recommend the right treatment.

What we can say is this: both semaglutide and tirzepatide represent a significant advance in metabolic medicine. Both have strong clinical evidence behind them. And both should only be used under medical supervision with a proper evaluation of your individual health.

If you are trying to choose between them based on social media posts or news headlines, you are working with incomplete information. A proper clinical consultation is the only way to make this decision well.

At Zelta, our clinicians specialise in metabolic health and weight management. They stay current on the latest evidence, understand the regulatory landscape in India, and can help you navigate the differences between available treatments clearly and without pressure.

When you book a consultation with Zelta, your doctor will:

• Review your complete health history and current medications
• Explain which treatment options are appropriate and available for your situation
• Discuss the evidence, expected outcomes, and realistic timelines
• Help you make an informed choice — not a rushed one

We believe the best medical decisions come from clarity, not hype. And our job is to give you that clarity.

Book a specialist consultation at zelta.in and get personalised, evidence-based guidance from a licensed clinician. A one-time consultation fee applies. If you proceed with a treatment plan, the amount paid is adjusted against the plan price.

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. The clinical trial results cited in this article reflect study averages from specific trial populations and may not predict individual outcomes. Drug availability, approved indications, and brand names vary by country and are subject to regulatory decisions by bodies such as the CDSCO in India, the FDA in the United States, and the EMA in Europe. Zelta does not endorse one medication over another. All treatment decisions are made by your prescribing clinician based on your individual health profile.